ARCA biopharma (NASDAQ:ABIO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of ARCA biopharma (NASDAQ:ABIO) in a research note published on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

ARCA biopharma Stock Performance

ABIO stock opened at $3.39 on Wednesday. The firm has a fifty day moving average price of $2.96 and a 200 day moving average price of $2.14. ARCA biopharma has a fifty-two week low of $1.56 and a fifty-two week high of $4.49. The firm has a market cap of $49.19 million, a PE ratio of -8.07 and a beta of 0.89.

ARCA biopharma (NASDAQ:ABIO) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ARCA biopharma stock. abrdn plc acquired a new position in shares of ARCA biopharma, Inc. (NASDAQ:ABIO) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 32,461 shares of the biopharmaceutical company’s stock, valued at approximately $55,000. Institutional investors own 56.44% of the company’s stock.

ARCA biopharma Company Profile

ARCA biopharma, Inc, a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.